Pfizer says it's ready to ramp up Paxlovid production. Experts say it's not that easy
Upon the FDA’s authorization of the first at-home Covid-19 pill to keep people out of the hospital, Pfizer CEO Albert Bourla announced his company has confidence it can make 120 million treatments in 2022, good for 3.6 billion tablets.
The drug has people excited: Paxlovid was found to reduce the risk of hospitalization by 89% in trial with the same safety profile as placebo, Pfizer reported. Not a single person dosed with the oral antiviral in the trial died of Covid-19, while 10 patients who received the placebo did.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.